These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 14999618)

  • 1. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002.
    Begier EM; Burwen DR; Haber P; Ball R;
    Clin Infect Dis; 2004 Mar; 38(6):771-9. PubMed ID: 14999618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; West DJ;
    Pharmacoepidemiol Drug Saf; 2002; 11(3):189-202. PubMed ID: 12051118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Typhim Vi vaccine in a postmarketing observational study.
    Marcus LC; Froeschle JE; Hill DR; Wolfe MS; Maus D; Connor B; Acosta AM; Rensimer ER; Roberts A; Dardick K
    J Travel Med; 2007; 14(6):386-91. PubMed ID: 17995534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.
    Moro PL; Arana J; Cano M; Menschik D; Yue X; Lewis P; Haber P; Martin D; Broder K
    Clin Infect Dis; 2012 Jun; 54(11):1608-14. PubMed ID: 22441652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.
    Niu MT; Ball R; Woo EJ; Burwen DR; Knippen M; Braun MM;
    Vaccine; 2009 Jan; 27(2):290-7. PubMed ID: 18992783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; Ward BJ; West DJ
    Pharmacoepidemiol Drug Saf; 2004 Dec; 13(12):825-40. PubMed ID: 15386719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System.
    Ball R; Braun MM; Mootrey GT;
    Clin Infect Dis; 2001 May; 32(9):1273-80. PubMed ID: 11303261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.
    Chang S; Ball R; Braun MM
    Vaccine; 2008 May; 26(19):2428-32. PubMed ID: 18406499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Typhoid fever in travelers: who should be targeted for prevention?
    Steinberg EB; Bishop R; Haber P; Dempsey AF; Hoekstra RM; Nelson JM; Ackers M; Calugar A; Mintz ED
    Clin Infect Dis; 2004 Jul; 39(2):186-91. PubMed ID: 15307027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.
    Kirkpatrick BD; McKenzie R; O'Neill JP; Larsson CJ; Bourgeois AL; Shimko J; Bentley M; Makin J; Chatfield S; Hindle Z; Fidler C; Robinson BE; Ventrone CH; Bansal N; Carpenter CM; Kutzko D; Hamlet S; LaPointe C; Taylor DN
    Vaccine; 2006 Jan; 24(2):116-23. PubMed ID: 16140433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of epidemiology in the introduction of vi polysaccharide typhoid fever vaccines in Asia.
    Acosta CJ; Galindo CM; Ochiai RL; Danovaro-Holliday MC; Page AL; Thiem VD; Park JK; Park E; Koo H; Wang XY; Abu-Elyazeed R; Ali M; Albert MJ; Ivanoff B; Pang T; Xu ZY; Clemens JD
    J Health Popul Nutr; 2004 Sep; 22(3):240-5. PubMed ID: 15609776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations.
    Kirkpatrick BD; Tenney KM; Larsson CJ; O'Neill JP; Ventrone C; Bentley M; Upton A; Hindle Z; Fidler C; Kutzko D; Holdridge R; Lapointe C; Hamlet S; Chatfield SN
    J Infect Dis; 2005 Aug; 192(3):360-6. PubMed ID: 15995948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.
    Rosenberg M; Sparks R; McMahon A; Iskander J; Campbell JD; Edwards KM
    Vaccine; 2009 Jul; 27(32):4278-83. PubMed ID: 19450636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety monitoring in vaccine development and immunization.
    Lee CJ; Lee LH; Lu CH; Huang YJ; Chu ML
    Acta Paediatr Taiwan; 2006; 47(1):7-13. PubMed ID: 17016963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
    Zhou WZ; Koo HW; Wang XY; Zhang J; Park JK; Zhu F; Deen J; Acosta CJ; Chen Y; Wang H; Galindo CM; Ochiai L; Park T; von Seidlein L; Xu ZY; Clemens JD
    Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.